Page 10 - Nasdaq Podd News Today

Insulet Co. (NASDAQ:PODD – Get Rating) has received a consensus rating of “Hold” from the fourteen research firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that […]

Cigna Investments Inc. New acquired a new position in shares of Insulet Co. (NASDAQ:PODD – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 747 shares of the medical instruments supplier’s stock, valued at approximately $220,000. A number of other hedge […]

Simplify Asset Management Inc. bought a new stake in Insulet Co. (NASDAQ:PODD – Get Rating) in the 4th quarter, HoldingsChannel reports. The firm bought 873 shares of the medical instruments supplier’s stock, valued at approximately $257,000. Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew […]

Insulet Co. (NASDAQ:PODD – Get Rating) shares were down 5.6% during trading on Thursday . The stock traded as low as $274.26 and last traded at $277.23. Approximately 204,643 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 711,383 shares. The stock had previously closed at $293.75. Analyst […]

StockNews.com started coverage on shares of Insulet (NASDAQ:PODD – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the medical instruments supplier’s stock. Several other research analysts have also weighed in on PODD. Stifel Nicolaus upped their target price on shares of Insulet from $300.00 […]

Insulet (NASDAQ: PODD) recently received a number of ratings updates from brokerages and research firms: 5/18/2023 – Insulet is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 5/8/2023 – Insulet had its price target raised by analysts at Barclays PLC from $292.00 to $329.00. 5/5/2023 – Insulet had its […]

William Blair Investment Management LLC cut its position in Insulet Co. (NASDAQ:PODD – Get Rating) by 40.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 301,601 shares of the medical instruments supplier’s stock after selling 200,951 shares during the quarter. William […]

Motley Fool Asset Management LLC lessened its position in shares of Insulet Co. (NASDAQ:PODD – Get Rating) by 7.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,261 shares of the medical instruments supplier’s stock after selling 103 shares during the quarter. Motley […]

Insulet (NASDAQ:PODD – Get Rating) had its price objective upped by Barclays from $292.00 to $329.00 in a research report report published on Monday morning, The Fly reports. Several other research firms have also recently weighed in on PODD. Raymond James increased their price target on shares of Insulet from $320.00 to $334.00 and gave […]

Washington Trust Advisors Inc. reduced its stake in Insulet Co. (NASDAQ:PODD – Get Rating) by 61.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 101 shares of the medical instruments supplier’s stock after selling 159 shares during the quarter. Washington Trust Advisors Inc.’s holdings […]